All News
Answering questions on how COVID-19 affects rheumatic patients
As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.
Read Article
Systemic Sclerosis and Physical Therapy
Systemic sclerosis (SSc) is a chronic fibrosing disease currently with no available cure.
Read Article
The folly of dietary restriction in contemporary gout? by @RichardPAConway
Dr. Conway discusses the abstracts presented at #ACR20
https://t.co/bJBKXKdftO https://t.co/Y5MXcNJQmS
Links:
Dr. John Cush RheumNow ( View Tweet)
Telemedicine Studies: A Trainee’s Perspective by Mrinalini Dey ( @DrMiniDey )
COVID-19 has shifted face to face to consultations--an important change in rheumatology practice. #ACR20
https://t.co/T2iUwE7XUo https://t.co/AyQ6X2fOJA
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jonathan Kay leads an international panel of rheumatologists to elicit their opinions on key abstracts at #ACR20. Panelists: @drdavidliew, @ejdein1, @MeralElRamahiMD, @RichardPAConway, @RHEUMarampa, and @jeffsparks
https://t.co/btZKgwvoSn https://t.co/Okdvx9HuNc
Links:
Dr. John Cush RheumNow ( View Tweet)
TAK & GCA differ in vessel involvement when it comes to the 👁👁
> TAK- large vessel lesions
> GCA- small vessel vasculitis
@RheumNow #ACR20 https://t.co/sa4VEvCKOt
sheila RHEUMarampa ( View Tweet)
I would usually be on a Transatlantic flight at this point post-ACR. Going #virtual is great as I never left. What did you miss most about a face to face conference? @RheumNow #ACR20
Dr. Antoni Chan synovialjoints ( View Tweet)
Dr. Cush and Dr. Kavanaugh recaps the #ACR20 meeting during #RheumatologyRoundUp highlighting important studies that were presented during the mtg and how they might impact practices. Log into https://t.co/3hCmtuN7kj to view this and all our videos/news stories. @RheumNow https://t.co/HgiA1QrdIX
Links:
k dao KDAO2011 ( View Tweet)
IgG4-RD tx: GCs are mainstay tx starting at 30-40mg/d tapered gradually but 30% of pts will have recurrences
Potential therapeutic targets to ⬇GC toxicity
✏B cell/plasmablasts (promising)
✏T cells (anecdotal)
@RheumNow #ACR20 https://t.co/X2NI3vFUgl
sheila RHEUMarampa ( View Tweet)
”Somatic mutation (in UBA1) may account for a significant fraction of adult-onset inflammatory disease” says Dr. Dan Kastner. Have you seen VEXAS in your clinic? #ACR20
Dr. Rachel Tate uptoTate ( View Tweet)
Reflecting on my first @ACRheum Congress- it wasn’t how I expected my first ACR to be. But #ACR20 was brilliant given the circumstances!
Easily one of the best virtual events I’ve attended- smooth platform, huge variety of sessions and efficient on-demand service.
@RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Spot diagnosis @RheumNow @CRASCRRheum #ACR20 hint this woman has 2 rheumatic diseases https://t.co/kEu9COJY3B
Janet Pope Janetbirdope ( View Tweet)
#ACR20 Closing Session: really poignant words from Dr Diane Kamen:
"This meeting...allowed people to 'go to the microphones'...people who wouldn't normally get up and ask questions during the sessions...allowed for a lot more exchange of ideas."
Couldn't agree more!
@RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
What would you use in multidrug failure RA pt from last tweet +RF nodules & keratitis failed 2 TNFi & 2 JAKi @RheumNow #ACR20 @CRASCRRheum
Janet Pope Janetbirdope ( View Tweet)
Low-dose steroids in RA: what's the harm, right?
(You probably know where I'm going with this)
ESPOIR 10y data: total events, and severe infections worse with dose and time
(cumulative 8.4g ≡ 5mg/d)
No doubt some residual confounding, but real risk!
#ACR20 ABST1998 @RheumNow https://t.co/BAQmOR1ped
David Liew drdavidliew ( View Tweet)
What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
Janet Pope Janetbirdope ( View Tweet)
Filgo decreased MRI inflammation of many structures early in Rx in SpA which seems novel says w Maksymowych 5M015 @RheumNow #ACR20 @CRASCRRheum #ACRbest https://t.co/LOOOn7Hjvp
Janet Pope Janetbirdope ( View Tweet)
Inadequate response to MTX, what next?
“Are you forward thinking or are you stuck in the past? Conceptually it is just amazing that you can take a PO tablet as potent as a TNF or IL6 blocker... & the side effects are not so appalling.”—Dr. GreggSilverman. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Summary of #ACR20 part C:
- A must see talk was the avacopan story
- IVIG for myositis does work! More than just anecdotal evidence now
- DIET is key to helping improve autoimmune dz!
- low dz activity RA pts should taper off of MTX 1st when also on TNFi @jeffsparks @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
@RheumNow #ACR20 abs1923 prosp cohort study of angiographic lesions in Takayasu’ &GCA: although infrequent new angio lesions more likely in TAK. Improvement is possible in both conditions, more likely to occur in TAK. Change in the branch arteries more dynamic than in the aorta https://t.co/2KsZ6o3vtP
Olga Petryna DrPetryna ( View Tweet)
